MEDI0457 Plus Durvalumab in HPV-associated HNSCC-Letter

Affiliations

¹ Department of Biostatistics, Clinical Research Support Center, Shizuoka Cancer Center, Shizuoka, Japan.
² Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
³ Division of Clinical Oncology, Shizuoka Cancer Center, Shizuoka, Japan.

Comment

Keita Mori et al. Clin Cancer Res. 2023.

. 2023 Jul 14;29(14):2735.

doi: 10.1158/1078-0432.CCR-23-0895.

¹ Department of Biostatistics, Clinical Research Support Center, Shizuoka Cancer Center, Shizuoka, Japan.
² Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
³ Division of Clinical Oncology, Shizuoka Cancer Center, Shizuoka, Japan.

No abstract available

Comment in

MEDI0457 Plus Durvalumab in HPV-associated HNSCC-Response.
Aggarwal C, Gong M, Kumar R. Aggarwal C, et al. Clin Cancer Res. 2023 Jul 14;29(14):2736. doi: 10.1158/1078-0432.CCR-23-1057. Clin Cancer Res. 2023. PMID: 37449358 No abstract available.

Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus-Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Aggarwal C, Saba NF, Algazi A, Sukari A, Seiwert TY, Haigentz M, Porosnicu M, Bonomi M, Boyer J, Esser MT, Cheng LI, Agrawal S, Jennings EC, Durham NM, Fraser K, Lissa D, Gong M, Ceaicovscaia N, Gascó Hernández A, Kumar R. Aggarwal C, et al. Clin Cancer Res. 2023 Feb 1;29(3):560-570. doi: 10.1158/1078-0432.CCR-22-1987. Clin Cancer Res. 2023. PMID: 36455147 Free PMC article.